Geneva: Unitaid and the World Health Organization today expressed their concerns over pharma giant Roche’s statement yesterday, warning of a global shortage of tocilizumab (brand name Actemra/RoActemra), an IL6 inhibitor WHO recommended in June, 2021 for use as a treatment for severe COVID-19 cases.
Tocilizumab can play a key role in decreasing mortality and reducing need for invasive mechanical ventilation among severely ill patients, when delivered alongside oxygen and corticosteroids.
“While we welcome and acknowledge that Roche has announced measures to address the shortage, we call on the company to ensure equitable allocation of current stocks of this medicine for all countries, including low- and middle-income countries,” Unitaid and WHO said in a joint statement today. They “strongly” encouraged Roche to facilitate technology transfer and knowledge and data sharing to broaden access to this important treatment.
Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, cheaply, and effectively, in low- and middle-income countries.
Also read: Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients, says new research
The Access to COVID-19 Tools (ACT) Accelerator partners are working with Roche to set up channels for distribution of tocilizumab in places where it is not yet in use, as part of their effort to support roll-out of effective new therapeutic products for COVID-19.
In addition, WHO has issued a call for Expression of Interest to its Prequalification programme to expand the number of quality-assured manufacturers of the drug and thus to increase global supplies.
“WHO and Unitaid remain committed to ensuring equitable access to medicines for treating patients with severe COVID-19 as a vital element of the effort to fight the pandemic everywhere and save lives,” they stated.
– global bihari bureau
